Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3472 Reduction of 64Cu-DOTATATE activity dose for somatostatin receptor PET imaging of patients with neuroendocrine neoplasms

Introduction: Frequent somatostatin receptor (SSR) PET imaging is key in the clinical management of patients with neuroendocrine neoplasms (NEN) and measures to reduce the radiation exposure should be pursued.

Conference:

Presenting Author:

Authors: Loft M, Carlsen E, Johnbeck C, Jensen C, Andersen F,

Keywords: 64Cu-DOTATATE, neuroendocrine neoplasm, PET imaging, SSR imaging,

#3443 Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy

Introduction: Non-invasive tools to improve prognostication are warranted in patients with neuroendocrine neoplasms (NEN). Expression of urokinase plasminogen activator receptor (uPAR) is present in many cancer types and associated with a poor outcome, but largely unknown in NEN. uPAR-targeted radionuclide therapy has proven effective in preclinical models and uPAR may be a potential target in NEN patients.

Conference:

Presenting Author: Carlsen E

Authors: Carlsen E, Loft M, Loft A, Berthelsen A, Langer S,

Keywords: urokinase plasminogen activator receptor (upar), neuroendocrine neoplasm, pet, prognosis, molecular imaging,

#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast

Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,

Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,

#2717 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms

Introduction: The degree of overexpression of somatostatin receptors in patients with neuroendocrine neoplasms (NEN) may reflect tumor differentiation and thus be associated with prognosis. Non-invasive quantification of receptor density is possible by somatostatin receptor imaging (SRI) using positron emission tomography (PET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carlsen E

Authors: Carlsen E, Johnbeck C, Binderup T, Loft M, Pfeifer A,

Keywords: 64Cu-dotatate, neuroendocrine neoplasm, progression-free survival, overall survival,

#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients

Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kjaer A

Authors: Binderup T, Johnbeck C, Loft A, Berthelsen A, Federspiel B,

Keywords: PET, PET/CT, imaging, survival,